Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,025,369
-
Share change
-
-452,282
-
Total reported value
-
$4,353,000
-
Price per share
-
$4.24
-
Number of holders
-
24
-
Value change
-
-$800,196
-
Number of buys
-
15
-
Number of sells
-
6
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q1 2017
As of 31 Mar 2017,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,025,369 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, KCG HOLDINGS, INC., Psagot Investment House Ltd., NORTHERN TRUST CORP, CITADEL ADVISORS LLC, BANK OF AMERICA CORP /DE/, Bank of New York Mellon Corp, and M&T Bank Corp.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.